Advances in the Treatment of Behcet's Disease.

Advances in the Treatment of Behcet's Disease.
复制标题

DOI:
10.1007/s11926-021-01011-z
复制
发表时间:
2021-05-20
影响因子:
5
通讯作者:
Direskeneli H
Direskeneli H
中科院分区:
医学2区
文献类型:
--
作者:
Alibaz-Oner F;Direskeneli H

文献摘要

参考文献

被引文献

相似文献

评估白塞病(BD)的当前治疗。不同表现的治疗方法的争议,无论是传统的免疫抑制剂(IS)或生物制剂,应选择,和难治性疾病的选择进行了讨论。糖皮质激素仍是诱导缓解的主要药物,硫唑嘌呤是维持期预防主要器官受累复发的一线常规IS。阿普斯特被证明是FDA批准的用于口腔溃疡的安全有效的选择。大量病例系列证实了TNFα抑制剂和干扰素-α的疗效和安全性。使用IL-1抑制剂、乌司奴单抗、阿司奴单抗和托珠单抗治疗难治性BD观察到有希望的结果。虽然传统的IS和生物制剂都有效地用于抑制BD的炎症,但在不同表现的管理中仍然需要明确的治疗策略。需要对新的生物制剂、抗凝剂以及IS与生物制剂联合使用的益处进行进一步的对照研究,以优化BD的管理。
To assess current management of Behcet’s disease (BD). Controversies on therapeutic approaches to different manifestations, whether conventional immunosuppressives (IS) or biologic agents, should be chosen, and options for refractory disease are discussed. Glucocorticoids are still the main agents for remission-induction and azathioprine the first-line conventional IS in maintenance phase to prevent relapses of major organ involvement. Apremilast is shown to be a safe and effective option approved by the FDA for oral ulcers. Large case series confirmed the efficacy and safety of TNFα inhibitors and Interferon-α. Promising results are observed with IL-1 inhibitors, ustekinumab, secukinumab, and tocilizumab for refractory BD. Although both conventional IS and biologic agents are effectively used to suppress inflammation in BD, there is still an unmet need for clear therapeutic strategies in the management for different manifestations. Further controlled studies with new biologic agents, anticoagulants and the benefit of concomitant IS usage with biologics are needed to optimize the management of BD.
DOI: 10.1093/rheumatology/keu266
发表时间: 2014-12-01
期刊: RHEUMATOLOGY
影响因子: 5.5
作者:
Calvo-Rio, Vanesa;Blanco, Ricardo;Gonzalez-Gay, Miguel A.
通讯作者: Gonzalez-Gay, Miguel A.
DOI: 10.1080/09273948.2017.1332768
发表时间: 2019-01-02
影响因子: 3.3
作者:
Celiker, Hande;Kazokoglu, Haluk;Direskeneli, Haner
通讯作者: Direskeneli, Haner
DOI: 10.1186/s12886-018-0929-5
发表时间: 2018-10-05
期刊: BMC ophthalmology
影响因子: 2
作者:
Celiker H;Kazokoglu H;Direskeneli H
通讯作者: Direskeneli H
DOI: 10.1080/09273948.2016.1206204
发表时间: 2017-01-01
影响因子: 3.3
作者:
Diwo, Eleonore;Gueudry, Julie;Bodaghi, Bahram
通讯作者: Bodaghi, Bahram
DOI: 10.1002/art.41026
发表时间: 2019-10-21
影响因子: 13.3
作者:
Atienza-Mateo, Belen;Luis Martin-Varillas, Jose;Blanco, Ricardo
通讯作者: Blanco, Ricardo